4//SEC Filing
Nolan Sean P. 4
Accession 0001209191-20-052462
CIK 0001806310other
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 4:38 PM ET
Size
11.5 KB
Accession
0001209191-20-052462
Insider Transaction Report
Form 4
Nolan Sean P.
DirectorChief Executive Officer
Transactions
- Conversion
Series A Preferred Stock
2020-09-28−1,000,000→ 0 total(indirect: See Footnote)→ Common Stock (1,089,500 underlying) - Conversion
Common Stock
2020-09-28+1,089,500→ 1,089,500 total(indirect: See Footnote) - Conversion
Common Stock
2020-09-28+1,601→ 1,091,101 total(indirect: See Footnote) - Conversion
Series B Preferred Stock
2020-09-28−1,470→ 0 total(indirect: See Footnote)→ Common Stock (1,601 underlying)
Footnotes (2)
- [F1]Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one for-1.0895 basis, and had no expiration date.
- [F2]The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of LLC, and is deemed to have sole voting and investment power with respect to the securities.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001569926
Filing Metadata
- Form type
- 4
- Filed
- Sep 29, 8:00 PM ET
- Accepted
- Sep 30, 4:38 PM ET
- Size
- 11.5 KB